Phaseline

Targets › CD371

CD371: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: the race on CD371, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Memorial Sloan Kettering Cancer CenterCD371-YSNVZ-IL-18 CAR T cells
anti-CD371 CAR-T cell therapy with IL-18
CD371Phase 1Refractory Acute Myeloid LeukemiaDec 2027

Conditions

Refractory Acute Myeloid Leukemia (1)

Modalities

other (1)

Companies

Memorial Sloan Kettering Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.